Novogen Limited, a biotechnology company, engages in the research and development of prescription drugs. Its products include ME-143, an analogue of Phenoxodiol that is Phase I clinical trials; NV-128, a novel mitochondrial inhibitor, which is in preclinical trials targeting a range of cancers; ME-344, which is in Phase I clinical trials for the treatment of tumors; and GLYC-101 Gel to stimulate and modulate the natural cascade of wound healing activities in several cell populations. The company’s products also comprise NV-143, an active against melanoma cells; NV-04 to treat cardiovascular diseases; NV-27, an oral agent to prevent arterial restenosis; NV-07α for the protection of mice against UV-induced inflammatory changes in the skin, and against UV-induced skin immune suppression; flavonoid anti-inflammatory molecules for general pain relief; and NV-52, a synthetic anti-inflammatory drug. It operates primarily in Australia, North America, Europe, and Asia. The company was founded in 1992 and is headquartered in North Ryde, Australia.

Key Statistics